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In the radioreceptor assay for growth hormone (RRA-GH) using [1251]iodo-hGH, hGH and human liver 
membrane particulate fractions as tracer, hormone standard and receptors, respectively, ovine placental lac- 
togen (oPL) is capable of inhibiting the binding of [1251]iodo-hGH in a parallel manner with hGH and in 
equipotency. Similarly, in the RRA-GH by employing [1251]iodo-oPL, oPL and human liver membrane par- 
ticulate fractions as tracer, hormone standard and receptors, respectively, hGH is also equipotent as oPL 
in inhibiting the binding of [1251]iodo-oPL in a parallel fashion. The addition of monoclonal antibodies 
against oPL in the assay was effective in inhibiting the binding of [lz51]iodo-oPL to human liver, but could 
not, however, inhibit the binding of [12SI]iodo-hGH to human liver. Furthermore, the addition of the mono- 
clonal antibodies in the RRA-GH did not affect the parallelism of the oPL standard but lowered the total 
binding of oPL. Our studies indicate that the structure of the binding sequence in oPL which binds to the 
GH receptor of human liver is not identical to the equivalent sequence of hGH and that the monoclonal 
antibodies compete with GH receptors in human liver for the binding of oPL. 
Monoclonal antibody 
1. INTRODUCTION 
Numerous studies on the mechanism(s) of action 
of polypeptide hormones have led to the concept 
that the primary event involves the binding of a 
hormone to a specific recognition site. This 
recognition site is also termed a ‘receptor’. The 
receptor is not only able to bind the hormone with 
high specificity and high affinity, but also is able 
via signal transduction to activate cellular pro- 
cesses after binding with the hormone. Within the 
last 15 years, receptors specific for pituitary 
polypeptide hormones such as growth hormone 
(GH), prolactin (PRL), gonadotropins (follicle- 
stimulating hormone (FSH) and luteinizing hor- 
mone (LH)), thyroid stimulating hormone (TSH), 
adrenocorticotropin and &endorphin, have been 
identified and characterized [l-8]. By employing a 
Ovine placental lactogen 
direct binding assay for growth hormone, it has 
been shown that the GH receptor is not only pre- 
sent in a wide range of animal tissues [9,10] but 
also in human liver and cultured lymphocytes 
[11,12]. We have previously shown that hGH 
specifically binds to human liver, whereas non- 
primate GH preparations display no cross- 
reactivity with hGH [13]. The only known hor- 
mone preparations that can compete with hGH for 
binding to human liver are human placental lac- 
togen (hPL) and ovine placental lactogen (oPL). 
The potencies of hPL and oPL were approx. l-10 
and 100% as potent as hGH, respectively. These 
observations raised the speculation that oPL and 
hGH might share a common (or identical) binding 
sequence (antigenic determinant) for binding to 
growth hormone receptor in human liver. 
Here we report the use of specific monoclonal 
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antibodies against oPL to inhibit the binding of 
[1251]iodo-hGH and [‘*‘I]iodo-oPL to human liver 
membrane particulate fractions. Our studies in- 
dicate that the structures of the GH-binding se- 
quence in hGH and oPL are not identical but could 
be similar. 
2. MATERIALS AND METHODS 
2.1. Hormone preparations 
Human growth hormone (NIAMDD-hGH-I-1, 
2.2 U/mg), ovine prolactin (NIAMDD-oPRL-I-l, 
32 U/mg), ovine growth hormone (NIADDK- 
oGH-I-3) and human placental lactogen (hPL) 
were kindly supplied by NIAMDD, NIH, USA. 
Ovine placental lactogen (oPL-I and oPL-II) 
were purified according to the methods that we 
have described elsewhere [14]. It is equipotent to 
oGH and oPRL in the radioreceptor assay for 
growth hormone (RRA-GH) [ 151 and for prolactin 
(RRA-PRL) [la], respectively. 
2.2. Radioreceptor assay for GH using human 
liver 
Human liver was obtained from post-mortem 
cadavers less than 6 h after death, at the Depart- 
ment of Pathology, Hotel-Dieu Hospital of 
Montreal. 
A RRA-GH was performed according to the 
method that we have described for RRA-oPL [17] 
using human liver membrane particulate fractions, 
[‘*‘I]iodo-hGH and hGH as receptors, tracer and 
hormone standard, respectively. 
2.3. Iodinations 
All iodinations were performed using the en- 
zymatic method of lactoperoxidase [18]. The 
specific activity for [1251]iodo-hGH and 1251-oPL 
was 75 and 78 /cCi/pg, respectively. 
2.4. Monoclonal antibodies against oPL 
The development of monoclonal antibodies to 
oPL has been described [19]. Monoclonal an- 
tibodies (ascites fluid) derived from three im- 
munoglobulin (1g)G secreting hybridomas (2C5, 
IB12 and 2C6) were used here. 
2.5. Effect of monoclonal antibodies on the 
binding of hGH and oPL 
To assess whether the monoclonal antibodies 
against oPL could inhibit the binding of [‘*‘I]iodo- 
hGH and [1251]iodo-oPL to human liver membrane 
particulate fractions, the following procedures 
were performed: assays were carried out in plastic 
tube (12 x 75 mm) containing 200 ~1 diluted ascites 
fluid and 100,ul diluted membrane particulate 
fractions (approx. 1 mg protein). All dilutions 
were made with 0.025 M Tris-HCl buffer, pH 7.6, 
containing 0.1% BSA and 10 mM MgCL. The in- 
cubation proceeded overnight at cold-room 
temperature. The reaction was terminated by the 
addition of 3 ml ice-cold 0.025 M Tris-HCI buffer, 
pH 7.6, containing 0.1% BSA, then centrifuged at 
780 x g for 30 min at 4°C. The supernatant was 
aspirated and the membrane-bound iodinated hor- 
mone in the precipitate was counted in an LKB 
autogamma counter. In the absence of diluted 
ascites fluid, approx. 25 and 30% of [1251]iodo- 
hGH and [‘*‘I]iodo-oPL of the added radioactivity 
were bound, respectively. Non-specific binding 
(tubes without ascites fluid and receptor added) ac- 
counted for < 10% of the maximum total binding. 
Results are expressed as % of control (in the 
absence of diluted ascites fluid) after subtracting 
the counts non-specifically bound. 
3. RESULTS 
In the RRA-hGH using [‘251]iodo-hGH, hGH 
and human liver membrane particulate fractions as 
tracer, hormone standard and receptors, respec- 
tively (fig. 1 A), oPL was able to inhibit the binding 
of [“‘Iliodo-hGH in a parallel manner to hGH 
standard and in equal potency to hGH, whereas 
hPL was only 5% as effective as hGH. oGH and 
oPRL were approx. 1-2070 as active as hGH. 
Similarly, when using [‘251]iodo-oPL as tracer in 
the RRA-GH as shown in fig.lB, oPL was also 
equipotent to hGH in inhibiting the binding of 
[1251]iodo-oPL to human liver membrane par- 
ticulate fractions, whereas hPL, oGH and oPRL 
were only 2% as active as the oPL standard. 
Fig.2A shows that the monoclonal antibodies 
derived from both 2C5 and lB12 hybridomas are 
able to inhibit the binding of [“‘I]iodo-oPL to 
human liver membrane particulate .fraction 
(greater than 65% inhibition at 1: 10 dilutions of 
ascites fluid), whereas monoclonal antibodies 
derived from 2C6 were ineffective in inhibiting the 
binding of [1251]iodo-oPL. None of the 
169 
Volume 201. number 1 FEBS LETTERS May 1986 
OPf?l OPRL 
2 80 
2 
80 
z 
8 60 60 
& 
“, 40 40 
8 
a 
20 20 
10 fO0 !000 1 10 fO0 to00 
HORMONE CONCENTRATfON (nghf ) 
Fig, 1. (A) Displacement curves for purified preparations of oPL-I, oPL-II, hGH, oPRL and oGH in the radioreceptor 
assay for growth hormone (RRA-GH). Human liver membrane particulate fractions were incubate with [“‘I]iodo- 
hGH in the presence of increasing concentrations of ‘cold’ hormone. The ordinate represents the [‘251]iodo-hGH bound 
to growth hormone binding site in the receptor preparation (total binding). In the absence of any added hormone the 
amount of total binding is approx. 25% using 1 mg membrane protein and is taken as control (100%). (B) Displacement 
curves of purified preparation of oPL-I, oPL-II, hGH, oPRL and oGH in the radioreceptor assay for placental actogen 
(RRA-PL). Human liver membrane particulate fractions were incubated with [‘2’I]iodo-oPL-I in the presence of oPL-I, 
oPL-II, hGH, oPRL and oGH. The total binding for [‘251]iodo-oPL-I is 30% using 1 mg membrane protein. The 
amount of [i2’I]iodo-oPL-I bound in the absence of cold hormone is taken as 100%. 
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monoclonal antibodies were effective in inhibiting 
the binding of [1251]iodo-hGH to human liver 
(fig.2B). 
Fig.3 depicts the effect of monoclon~ an- 
tibodies in the RRA-GH using [‘251]iodo-oPL as 
tracer. The addition of monoclonal antibodies did 
not affect the dose-response curve (parallelism) of 
the oPL standard in the assay. It did, however, 
lower the total binding of the iodinated oPL to the 
receptors. 
Fig.2. (A) Inhibition of binding of [“‘I]iodo-oPL to 
human liver membrane particulate fractions by 
monoclonal antibodies against oPL. The total binding 
for [‘251]iodo-oPL without monoclonal antibodies 
added is approx. 27% and is expressed as control 
(100%). Hybridoma 2CS (o---O), lB12 (o--o) and 
2C6 (h--b). (B) Inhibition of binding of I’251]iodo- 
hGH to human liver by monoclonal antibodies against 
oPL. The total binding for [‘2’I]iodo-hGH without 
monoclonal antibodies added is approx. 30% and is 
expressed as control (100%). Symbols same as in A. 
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Fig.3 Displacement curves of oPL standard in the RRA- 
GH using human liver membrane particulate fractions 
and iodinated oPL as receptors and tracer, respectively. 
The total binding for oPL standard without monoclonal 
antibodies is 37.95% (C--O). The total bindings for 
oPL with monoclonal antibodies added for 2C5 at 
dilutions of 1: 10000 (ti) and 1: 100 (H) and for 
lB12 at dilutions of 1: 10000 (o--o) and 1: 100 
(a--~) are 37.78,28.89,24.44 and 12.0%, respectively. 
4. DISCUSSION 
Lesniak et al. [20] have reported that human 
lymphocyte receptor for GH is species specific, 
and that non-primate GHs fail to compete for the 
GH receptors. The same features were observed by 
Carr and Friesen [l I] using human liver 
radioreceptor assay. 
It is interesting to note that only oPL and hGH 
compete equally either against [“‘I]iodo-hGH or 
[“‘I]iodo-oPL in the RRA-GH using human liver 
membrane particulate fractions as receptors 
(fig. 1). These observations raised the prospect hat 
the binding sequence in both oPL and hGH might 
be identical or very similar. In our current studies, 
we have successfully inhibited, by monoclonal an- 
tibodies against oPL, the binding of [1251]iodo- 
oPL but not the binding of [“‘IJiodo-hGH to 
human liver. These observations indicate that the 
structure of GH-binding sequence in oPL is dif-, 
ferent from that in hGH. Nevertheless, we could 
not rule out the possibility that the GH-binding se- 
quences in both oPL and hGH might be similar 
(partial homology). Indeed, we are currently in- 
vestigating the structure of GH-binding sequence 
in oPL. A definite answer should become available 
in the near future. 
Furthermore, our studies have shown that the 
addition of monoclonal antibodies in the RRA-GH 
does not affect the parallelism of oPL standard 
curves (fig.3). These studies suggest that our 
monoclonal antibodies are probably competing 
with the receptors for hormone-binding sequence 
in the oPL molecule. 
Monoclonal antibodies directed to hGH or hPL 
have been reported by various authors [21-231. 
Some of these monoclonal antibodies were shown 
to be able to inhibit the biological effect of hGH 
and hPL in vitro, i.e. growth of rat NB2 lym- 
phoma cells (231. In this regard, whether our 
monoclonal antibodies could also inhibit the 
biological effect of oPL in vitro and in vivo re- 
mains to be determined. 
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